ArticleInternational orthopaedics2026
The effectiveness and safety of tripod-enhanced percutaneous reconstruction combined with local tumour inactivation for periacetabular metastases: a long-term follow-up study.
Article in International orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPeriacetabular metastases often cause severe pain and functional impairment, whereas open acetabular reconstruction carries substantial morbidity that may delay systemic cancer treatment. This study evaluated the safety and effectiveness of tripod-enhanced percutaneous reconstruction combined with microwave ablation (MWA) for periacetabular metastases.
methodsWe retrospectively reviewed 31 patients (mean age, 59.5 ± 14.4 years; 18 men, 13 women) with acetabular metastases treated with this technique. Clinical outcomes were assessed preoperatively and at three, six and 12 months postoperatively and final follow-up. Endpoints included pain (VAS), functional status (ECOG), weight-bearing ability, perioperative blood loss, complications, and survival.
resultsFourteen of 31 patients died during follow-up, with a median postoperative survival of 35.0 months (95% CI, 17.5-52.5). Mean VAS scores improved significantly from 5.85 ± 1.63 preoperatively to 2.48 ± 1.25, 1.22 ± 0.95, and 1.59 ± 1.10 at three, six and 12 months, respectively (all p < 0.001). ECOG performance status also improved from 2.44 ± 1.00 to 1.60 ± 0.65, 1.48 ± 0.59, and 1.50 ± 0.67 at three, six and 12 months. In patients surviving beyond one year (12-41 months), pain relief and functional improvement were maintained. No implant failure, infection, or treatment delay occurred. At final follow-up, 21 patients (67.7%) achieved independent ambulation, seven (22.6%) required assistive devices, and three (9.7%) received additional radiotherapy. No patient underwent total hip arthroplasty.
conclusionTripod-enhanced percutaneous reconstruction combined with MWA is a safe, minimally invasive, and effective option for periacetabular metastases, providing durable pain relief and improved mobility.
Indexed as
Identifiers
42521887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.